Complement Inhibitors for Degos Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Degos' disease, a rare and aggressive vasculopathy, are ineffective and lack predictive methods for patient response, leading to high mortality rates due to the systemic form of the disease.
Innovation Solution
Administration of a complement inhibitor, such as the humanized anti-C5 antibody eculizumab, to reduce complement activity in patients, either as a standalone treatment or in combination with interferon alpha inhibitors and B cell-targeted therapies, to manage and prevent the progression of Degos' disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard medical treatments are used for Degos' disease, then treatment coverage is provided, but treatment efficacy is marginal and inconsistent
Solution Approach 1:
The patent changes the therapeutic parameter from conventional immunosuppressants to complement inhibitors (anti-C5, anti-C3 antibodies), fundamentally altering the mechanism of action to target the complement system specifically. This parameter change resolves the contradiction by providing both high efficacy through selective complement inhibition and adaptability through biomarker-guided patient selection based on complement activation status
Solution Approach 2:
The patent implements feedback through biomarker monitoring (complement activation markers, cytokine profiles) to identify patients who will respond to complement inhibition therapy. This feedback mechanism enables predictive patient selection, resolving the contradiction between treatment efficacy and predictive capability by using diagnostic markers to guide therapeutic intervention
2Reliability
If aggressive systemic Degos' disease is left untreated, then natural disease progression occurs, but mortality rate is extremely high within 1-12 years
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism (complement system activation) from the complex systemic disease process. By isolating and inhibiting the complement pathway as the key driver of thrombosis and organ damage, the treatment simplifies the approach to managing aggressive Degos' disease, resolving the contradiction between survival rate improvement and treatment complexity
Solution Approach 2:
The patent changes the therapeutic parameter to complement inhibition, which directly addresses the underlying pathogenesis of aggressive Degos' disease. This targeted parameter change improves survival rates by blocking the complement-mediated thrombotic cascade while maintaining manageable treatment complexity through the use of monoclonal antibodies with established administration protocols
Data Source
AI summary
The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and/or an inhibitor of interferon alpha, and the use of the compositions in methods for treating or preventing Degos' disease in a subject. In some embodiments, the inhibitor is an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or to a biologically-active fragment of C5 such as C5a or C5b. In some embodiments, the inhibitor is an antibody, or an antigen-binding fragment thereof, that binds to interferon alpha or to an interferon alpha receptor.